These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 6425455)

  • 1. L-deprenyl plus L-phenylalanine in the treatment of depression.
    Birkmayer W; Riederer P; Linauer W; Knoll J
    J Neural Transm; 1984; 59(1):81-7. PubMed ID: 6425455
    [TBL] [Abstract][Full Text] [Related]  

  • 2. l-Deprenyl in atypical depressives.
    Quitkin FM; Liebowitz MR; Stewart JW; McGrath PJ; Harrison W; Rabkin JG; Markowitz J; Davies SO
    Arch Gen Psychiatry; 1984 Aug; 41(8):777-81. PubMed ID: 6430257
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differential efficacy of L-deprenyl, a selective MAO type-B inhibitor, in endogenous and nonendogenous depression.
    Mann JJ; Frances A; Peselow ED; Gershon S
    Psychopharmacol Bull; 1982 Oct; 18(4):182-4. PubMed ID: 6818606
    [No Abstract]   [Full Text] [Related]  

  • 4. A controlled study of the antidepressant efficacy and side effects of (-)-deprenyl. A selective monoamine oxidase inhibitor.
    Mann JJ; Aarons SF; Wilner PJ; Keilp JG; Sweeney JA; Pearlstein T; Frances AJ; Kocsis JH; Brown RP
    Arch Gen Psychiatry; 1989 Jan; 46(1):45-50. PubMed ID: 2491941
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A placebo-controlled trial of L-deprenyl in atypical depression.
    McGrath PJ; Stewart JW; Harrison W; Wager S; Nunes EN; Quitkin FM
    Psychopharmacol Bull; 1989; 25(1):63-7. PubMed ID: 2505303
    [No Abstract]   [Full Text] [Related]  

  • 6. The relative efficacy of l-deprenyl, a selective monoamine oxidase type B inhibitor, in endogenous and nonendogenous depression.
    Mann JJ; Frances A; Kaplan RD; Kocsis J; Peselow ED; Gershon S
    J Clin Psychopharmacol; 1982 Feb; 2(1):54-7. PubMed ID: 6802883
    [No Abstract]   [Full Text] [Related]  

  • 7. Biochemical effects of L-deprenyl in atypical depressives.
    Liebowitz MR; Karoum F; Quitkin FM; Davies SO; Schwartz D; Levitt M; Linnoila M
    Biol Psychiatry; 1985 May; 20(5):558-65. PubMed ID: 3921065
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Platelet monoamine oxidase inhibition by deprenyl and tranylcypromine: implications for clinical use.
    Simpson GM; Frederickson E; Palmer R; Pi E; Sloane RB; White K
    Biol Psychiatry; 1985 Jun; 20(6):684-7. PubMed ID: 3922441
    [No Abstract]   [Full Text] [Related]  

  • 9. Amphetamine and 2-phenylethylamine in post-mortem Parkinsonian brain after (-)deprenyl administration.
    Reynolds GP; Riederer P; Sandler M; Jellinger K; Seemann D
    J Neural Transm; 1978; 43(3-4):271-7. PubMed ID: 745019
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rapid treatment of depression with selegiline-phenylalanine combination.
    Sabelli HC
    J Clin Psychiatry; 1991 Mar; 52(3):137. PubMed ID: 1900832
    [No Abstract]   [Full Text] [Related]  

  • 11. Deprenyl (selegiline) in the treatment of Parkinson's disease.
    Rinne UK
    Acta Neurol Scand Suppl; 1983; 95():107-11. PubMed ID: 6428141
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 2-Phenylethylamine and amphetamine in human brain: effects of L-deprenyl in Parkinson's disease [proceedings].
    Reynolds GP; Riederer P; Sandler M
    Biochem Soc Trans; 1979 Feb; 7(1):143-5. PubMed ID: 437259
    [No Abstract]   [Full Text] [Related]  

  • 13. Deprenyl (selegiline) combined with levodopa and a decarboxylase inhibitor in the treatment of Parkinson's disease.
    Presthus J; Hajba A
    Acta Neurol Scand Suppl; 1983; 95():127-33. PubMed ID: 6428145
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Current controversies in the use of selegiline hydrochloride.
    Lees AJ
    J Neural Transm Suppl; 1987; 25():157-62. PubMed ID: 3123602
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anti-depressant potentiation of 5-hydroxytryptophan by L-deprenyl, an MAO "type B" inhibitor.
    Mendlewicz J; Youdim MB
    J Neural Transm; 1978; 43(3-4):279-86. PubMed ID: 745020
    [No Abstract]   [Full Text] [Related]  

  • 16. Deprenyl in Parkinson's disease.
    Lancet; 1982 Sep; 2(8300):695-6. PubMed ID: 6126632
    [No Abstract]   [Full Text] [Related]  

  • 17. Deprenyl in Parkinson disease.
    Eisler T; Teräväinen H; Nelson R; Krebs H; Weise V; Lake CR; Ebert MH; Whetzel N; Murphy DL; Kopin IJ; Calne DB
    Neurology; 1981 Jan; 31(1):19-23. PubMed ID: 6161320
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oscillations in performance in levodopa-treated parkinsonians: treatment with bromocriptine and L-deprenyl.
    Lander CM; Lees A; Stern G
    Clin Exp Neurol; 1979; 16():197-203. PubMed ID: 121706
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Attempts to attenuate the 'cheese effect'. Combined drug therapy in depressive illness.
    Pare CM; Al Mousawi M; Sandler M; Glover V
    J Affect Disord; 1985 Sep; 9(2):137-41. PubMed ID: 2932486
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical efficacy of deprenyl, a specific inhibitor of MAOB.
    Psychopharmacol Bull; 1983; 19(3):328-42. PubMed ID: 6314420
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.